Does the media favor ALNY or IBRX?

In the previous week, Alnylam Pharmaceuticals had 7 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for Alnylam Pharmaceuticals and 4 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.50 beat Alnylam Pharmaceuticals' score of 0.26 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer ROIV or IBRX?

In the previous week, Roivant Sciences had 3 more articles in the media than ImmunityBio. MarketBeat recorded 7 mentions for Roivant Sciences and 4 mentions for ImmunityBio. Roivant Sciences' average media sentiment score of 1.25 beat ImmunityBio's score of 0.50 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better valuation & earnings, INCY or IBRX?

Incyte has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 4.70 $1.29B $7.85 15.19 ImmunityBio $113.29M 70.21 -$351.40M -$0.97 N/A

Is INCY or IBRX more profitable?

Incyte has a net margin of 27.71% compared to ImmunityBio's net margin of -598.55%. Incyte's return on equity of 29.93% beat ImmunityBio's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% ImmunityBio -598.55% N/A -51.65%

Does the media refer more to INCY or IBRX?

In the previous week, Incyte had 1 more articles in the media than ImmunityBio. MarketBeat recorded 5 mentions for Incyte and 4 mentions for ImmunityBio. Incyte's average media sentiment score of 1.69 beat ImmunityBio's score of 0.50 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is IBRX or BNTX more profitable?

BioNTech has a net margin of -63.54% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% BioNTech -63.54% -6.86% -6.00%

Does the media favor IBRX or BNTX?

In the previous week, BioNTech had 7 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for BioNTech and 4 mentions for ImmunityBio. BioNTech's average media sentiment score of 0.58 beat ImmunityBio's score of 0.50 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BioNTech 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, IBRX or MRNA?

ImmunityBio has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 70.21 -$351.40M -$0.97 N/A Moderna $1.94B 12.94 -$2.82B -$7.99 N/A

Is IBRX or MRNA more profitable?

Moderna has a net margin of -141.43% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% Moderna -141.43% -28.30% -19.39%

Does the media favor IBRX or MRNA?

In the previous week, Moderna had 7 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for Moderna and 4 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.50 beat Moderna's score of 0.35 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Moderna 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

ImmunityBio (IBRX) Competitors

$7.52 -0.14 (-1.76%)

As of 10:44 AM Eastern

Compare

IBRX vs. ALNY, ROIV, INCY, BNTX, and MRNA

Should you buy ImmunityBio stock or one of its competitors? ImmunityBio's main competitors and comparable companies include Alnylam Pharmaceuticals (ALNY), Roivant Sciences (ROIV), Incyte (INCY), BioNTech (BNTX), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ImmunityBio compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Alnylam Pharmaceuticals had 7 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for Alnylam Pharmaceuticals and 4 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.50 beat Alnylam Pharmaceuticals' score of 0.26 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a net margin of 15.26% compared to ImmunityBio's net margin of -598.55%. Alnylam Pharmaceuticals' return on equity of 84.93% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
ImmunityBio	-598.55%	N/A	-51.65%

Alnylam Pharmaceuticals has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.24	$313.75M	$5.38	41.64
ImmunityBio	$113.29M	70.21	-$351.40M	-$0.97	N/A

Alnylam Pharmaceuticals presently has a consensus target price of $396.72, indicating a potential upside of 77.09%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 89.21%. Given ImmunityBio's higher probable upside, analysts plainly believe ImmunityBio is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats ImmunityBio on 13 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Roivant Sciences has higher earnings, but lower revenue than ImmunityBio. Roivant Sciences is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,160.61	-$299.77M	-$0.53	N/A
ImmunityBio	$113.29M	70.21	-$351.40M	-$0.97	N/A

Roivant Sciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market.

In the previous week, Roivant Sciences had 3 more articles in the media than ImmunityBio. MarketBeat recorded 7 mentions for Roivant Sciences and 4 mentions for ImmunityBio. Roivant Sciences' average media sentiment score of 1.25 beat ImmunityBio's score of 0.50 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 66.1% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ImmunityBio has a net margin of -598.55% compared to Roivant Sciences' net margin of -3,534.96%. ImmunityBio's return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
ImmunityBio	-598.55%	N/A	-51.65%

Roivant Sciences currently has a consensus price target of $35.14, indicating a potential downside of 3.19%. ImmunityBio has a consensus price target of $14.20, indicating a potential upside of 89.21%. Given ImmunityBio's higher possible upside, analysts plainly believe ImmunityBio is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Roivant Sciences beats ImmunityBio on 11 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to Incyte?

Incyte (NASDAQ:INCY) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Incyte has a net margin of 27.71% compared to ImmunityBio's net margin of -598.55%. Incyte's return on equity of 29.93% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
ImmunityBio	-598.55%	N/A	-51.65%

Incyte has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.70	$1.29B	$7.85	15.19
ImmunityBio	$113.29M	70.21	-$351.40M	-$0.97	N/A

97.0% of Incyte shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 66.1% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Incyte has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market.

Incyte currently has a consensus target price of $120.65, suggesting a potential upside of 1.19%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 89.21%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Incyte had 1 more articles in the media than ImmunityBio. MarketBeat recorded 5 mentions for Incyte and 4 mentions for ImmunityBio. Incyte's average media sentiment score of 1.69 beat ImmunityBio's score of 0.50 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Incyte beats ImmunityBio on 12 of the 16 factors compared between the two stocks.

How does ImmunityBio compare to BioNTech?

ImmunityBio (NASDAQ:IBRX) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ImmunityBio has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	70.21	-$351.40M	-$0.97	N/A
BioNTech	$3.25B	7.13	-$1.29B	-$7.83	N/A

In the previous week, BioNTech had 7 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for BioNTech and 4 mentions for ImmunityBio. BioNTech's average media sentiment score of 0.58 beat ImmunityBio's score of 0.50 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
BioNTech	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a net margin of -63.54% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
BioNTech	-63.54%	-6.86%	-6.00%

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 89.21%. BioNTech has a consensus price target of $127.81, indicating a potential upside of 39.67%. Given ImmunityBio's higher probable upside, analysts plainly believe ImmunityBio is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

ImmunityBio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Summary

BioNTech beats ImmunityBio on 10 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to Moderna?

ImmunityBio (NASDAQ:IBRX) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Moderna has a net margin of -141.43% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Moderna	-141.43%	-28.30%	-19.39%

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 89.21%. Moderna has a consensus price target of $42.13, indicating a potential downside of 33.10%. Given ImmunityBio's stronger consensus rating and higher possible upside, equities analysts clearly believe ImmunityBio is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88

ImmunityBio has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	70.21	-$351.40M	-$0.97	N/A
Moderna	$1.94B	12.94	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 7 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for Moderna and 4 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.50 beat Moderna's score of 0.35 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Moderna	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ImmunityBio beats Moderna on 10 of the 16 factors compared between the two stocks.

Get ImmunityBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBRX vs. The Competition

Export

Metric	ImmunityBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.96B	$3.69B	$6.96B	$13.10B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-7.75	10.23	269.57	25.32
Price / Sales	70.21	1,285.96	595.01	100.00
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	-7.58	17.54	13.06	6.29
Net Income	-$351.40M	-$13.32M	$3.45B	$347.70M
7 Day Performance	-1.77%	0.19%	0.47%	0.89%
1 Month Performance	-4.76%	-0.03%	1.11%	0.85%
1 Year Performance	176.94%	53.11%	66.38%	20.25%

ImmunityBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBRX ImmunityBio	2.4997 of 5 stars	$7.51 -1.9%	$14.20 +89.2%	+171.3%	$7.96B	$113.29M	N/A	590
ALNY Alnylam Pharmaceuticals	4.8295 of 5 stars	$228.16 +4.2%	$396.72 +73.9%	-47.5%	$30.44B	$3.71B	42.29	2,770
ROIV Roivant Sciences	1.733 of 5 stars	$34.75 +0.4%	$33.59 -3.3%	+203.4%	$24.99B	$8.26M	N/A	860	Positive News
INCY Incyte	3.6297 of 5 stars	$120.99 +0.3%	$120.40 -0.5%	+40.4%	$24.53B	$5.14B	15.42	2,844	Positive News Analyst Forecast
BNTX BioNTech	3.3461 of 5 stars	$90.90 -0.5%	$128.13 +41.0%	-18.3%	$22.97B	$3.25B	N/A	7,807

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBRX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmunityBio (IBRX) Competitors

IBRX vs. ALNY, ROIV, INCY, BNTX, and MRNA

How does ImmunityBio compare to Alnylam Pharmaceuticals?

Summary

How does ImmunityBio compare to Roivant Sciences?

Summary

How does ImmunityBio compare to Incyte?

Summary

How does ImmunityBio compare to BioNTech?

Summary

How does ImmunityBio compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX vs. The Competition

ImmunityBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmunityBio (IBRX) Competitors

IBRX vs. ALNY, ROIV, INCY, BNTX, and MRNA

How does ImmunityBio compare to Alnylam Pharmaceuticals?

Does the media favor ALNY or IBRX?

Is ALNY or IBRX more profitable?

Which has preferable earnings and valuation, ALNY or IBRX?

Do analysts recommend ALNY or IBRX?

Do institutionals and insiders have more ownership in ALNY or IBRX?

Which has more volatility & risk, ALNY or IBRX?

Summary

How does ImmunityBio compare to Roivant Sciences?

Which has stronger valuation & earnings, ROIV or IBRX?

Which has more risk & volatility, ROIV or IBRX?

Does the media prefer ROIV or IBRX?

Do institutionals & insiders believe in ROIV or IBRX?

Is ROIV or IBRX more profitable?

Do analysts rate ROIV or IBRX?

Summary

How does ImmunityBio compare to Incyte?

Is INCY or IBRX more profitable?

Which has better valuation & earnings, INCY or IBRX?

Do insiders & institutionals have more ownership in INCY or IBRX?

Which has more risk & volatility, INCY or IBRX?

Do analysts recommend INCY or IBRX?

Does the media refer more to INCY or IBRX?

Summary

How does ImmunityBio compare to BioNTech?

Do institutionals & insiders believe in IBRX or BNTX?

Which has stronger earnings & valuation, IBRX or BNTX?

Does the media favor IBRX or BNTX?

Is IBRX or BNTX more profitable?

Do analysts prefer IBRX or BNTX?

Which has more volatility & risk, IBRX or BNTX?

Summary

How does ImmunityBio compare to Moderna?

Which has more risk & volatility, IBRX or MRNA?

Do insiders and institutionals believe in IBRX or MRNA?

Is IBRX or MRNA more profitable?

Do analysts rate IBRX or MRNA?

Which has preferable valuation and earnings, IBRX or MRNA?

Does the media favor IBRX or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX vs. The Competition

ImmunityBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools